Abstract:Background Atherosclerosis is a systemic disease involving multiple blood vessels and a major cause of cardiovascular disease. Current treatment methods (e.g., statins) for atherosclerosis can effectively reduce the risk of cardiovascular diseases, but they are insufficient to completely reverse existing atherosclerosis. Macrophages play a central role in atherosclerosis development. Chemokines, the main mediators of macrophage chemotaxis, are important in immune and inflammatory responses. The effects of chemokines on and mechanisms involved in atherosclerosis are unknown. This study preliminarily investigated these effects and mechanisms via bioinformatics methods. Methods In this study, data on chemokine ligands and receptors were obtained by mining public databases (the NCBI-GEO database, ArrayExpress database and single-cell RNA sequencing (scRNA-seq) database), and an extensive literature search was performed. The expression levels of chemokines in mouse tissues were analyzed via ArrayExpress via Metascape software for signaling pathway enrichment, scRNA-seq data for chemokine expression in atherosclerotic plaque progression and regression, and GEO2R data for chemokine expression during macrophage polarization. Ingenuity Pathway Analysis software was used to analyze regulatory factors such as transcription factors and microRNAs that are significantly differentially expressed upstream of chemokines in macrophage polarization. Finally, a model of the chemokine regulation of AS was established on the basis of the above results. Results There are 5 main findings: 1. In atherosclerosis, chemokines are regulated by transcription factors and microRNAs. 2. The transcription factor STAT1 promotes the polarization of dormant (M0) macrophages into classically activated (M1) macrophages and alternative activated (M2) macrophages by regulating chemokines. The transcription factors STAT1, IRF7 and IRF1 regulate the polarization of M0 macrophages into M2a and M2b macrophages via different chemokines. For example, some transcription factors promote M1 polarization of M0 macrophages through CCL4, but M2 macrophage polarization is regulated via CCL19, CCL5 and CCR7. 3. Transcription factors can promote and inhibit while miRNAs can only inhibit atherosclerosis. 4. CCL4 existed in all five different chemokine-regulated macrophage models, while CXCL3 only existed in the M2b macrophage transcriptional regulation model, indicating that CXCL3 may promote the M2b type macrophages polarization of M0 macrophages. 5. CCL5 and CCR7 can promote the M2a macrophages and M2b macrophages polarization of M0 macrophages. Conclusions 1. Atherosclerosis can be treated by regulating chemokines and regulating the polarization of macrophages. 2. The chemokines CCL4, CCL5, CCL8, CCL19, CXCL3, CXCL10, CXCL13 and CCR7 may play key roles in the progression and regression of atherosclerosis.

Therapeutic targeting of chemokine interactions in atherosclerosis

Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential

Chemokines in atherosclerosis: an update

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

Targeting immune cell recruitment in atherosclerosis

Cytokines and atherosclerosis: a comprehensive review of studies in mice

Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression

Atherosclerosis: cell biology and lipoproteins--new mechanistic links in atherosclerosis: chemokines mediating the effects of lipids, platelets and dendritic cells.

Chemokine Ligands and Receptors Regulate Macrophage Polarization in Atherosclerosis: a Comprehensive Database Mining Study

CXCR3-binding chemokines: novel multifunctional therapeutic targets

Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice

Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis

Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice

The Entry and Egress of Monocytes in Atherosclerosis: A Biochemical and Biomechanical Driven Process

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Novel Anti-Inflammatory Peptides Based on Chemokine-Glycosaminoglycan Interactions Reduce Leukocyte Migration and Disease Severity in a Model of Rheumatoid Arthritis

Clinical Significance of Chemokine Receptor Antagonists

A New Class Of Chemokine Analogs As Useful Research Tools To Study Chemokine Receptor Function And Promising Therapeutic Agents.

Pharmacological therapy targeting the immune response in atherosclerosis

CCL18 aggravates atherosclerosis by inducing CCR6-dependent T-cell influx and polarization

Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis